

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Drewe et al.

Appl. No. 09/836,548

Filed: April 18, 2001

For:

Substituted 1,4-Thiazepine and Analogs as Activators of Caspases and Inducers of Apoptosis and the

Use Thereof

Confirmation No.: 6789

Art Unit: 1624

Examiner: Coleman, B.

Atty. Docket: 1735.0450001/RWE/RAS

Amendment And Reply Under 37 C.F.R. § 1.111

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated October 3, 2003, (PTO Prosecution File Wrapper Paper No. 13), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete-listing-of-all-of-the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

RECEIVED

OCT 3 1 2003

TECH CENTER 1600/2900

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.